Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Neuroimmunology: Phase II trial demonstrates efficacy of erythropoietin in optic neuritis.
Dimethyl fumarate for multiple sclerosis.
[Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b].
Novel MS Drugs Advance
The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study.
Rituximab for relapsing-remitting multiple sclerosis.
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
The Effects of IFN-β 1a on the Expression of Inflammasomes and Apoptosis-Associated Speck-Like Proteins in Multiple Sclerosis Patients.
Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS.
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Acorda Therapeutics announces Hatch-Waxman extension of AMPYRA® (dalfampridine) sustained-release formulation patent
Epigenetics of Multiple Sclerosis: An Updated Review.
Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997-2008.
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis.
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse.
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
The force awakens: insights into the origin and formation of microglia.
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview.
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
The endocannabinoid system and multiple sclerosis.

Pages